Nanoform Finland Plc (“Nanoform”) today announced a strategic partnership whereby CBC Co., Ltd. (“CBC”), will utilize its extensive experience in the Japanese pharmaceutical industry to identify opportunities for Nanoform’s cutting-edge nanomedicine engineering technologies. Nanoformed medicines have been shown to overcome innovators’ drug bioavailability issues and reduce dose size and pill burden to improve patient-acceptance, both for new drugs and reformulations of existing products.“This strategic partnership with CBC represents a significant milestone in our ongoing effort to bring our cutting-edge nanotechnology to enable improved medicines for patients around the world.

Nanoform芬兰有限公司（“Nanoform”）今天宣布建立战略合作伙伴关系，CBC有限公司（“CBC”）将利用其在日本制药行业的丰富经验，为Nanoform的尖端纳米医学工程技术寻找机会。纳米药物已被证明可以克服创新者的药物生物利用度问题，减少剂量大小和药丸负担，以提高患者对新药和现有产品的重新配方的接受程度。“与CBC的这一战略伙伴关系是我们不断努力的一个重要里程碑，我们正在努力将尖端的纳米技术应用于为世界各地的患者提供改进的药物。

Japan is a key country for innovative drug development, and we are excited to work with a partner that shares our commitment to bringing meaningful innovation to patients faster,” said Christian Jones, Chief Commercial Officer at Nanoform. “CBC has a deep understanding of the Japanese market, which will be instrumental in tailoring Nanoform’s services to meet the specific needs and preferences of biopharma customers there.”Shinya Miyairi, Managing Executive Officer at CBC said, “CBC is honored to partner with Nanoform and to represent them in Japan.

日本是创新药物开发的关键国家，我们很高兴能与一个合作伙伴合作，共同致力于更快地为患者带来有意义的创新，”Nanoform首席商务官克里斯蒂安·琼斯（ChristianJones）表示。“CBC对日本市场有着深刻的了解，这将有助于定制Nanoform的服务，以满足那里生物制药客户的特定需求和偏好。”CBC常务执行官宫井信亚（ShinyaMiyairi）表示，“CBC很荣幸与Nanoform合作，并在日本代表他们。

We believe that Nanoform’s technologies represent a great fit for the Japanese market where the ability to provide medicines with higher bioavailability and fewer and smaller doses are important for success.”Nanoform technology has been effective in several in vitro and in vivo studies across multiple routes of administration including oral, inhaled, ophthalmic and injectables, and across multiple molecule types such as enzalutamide and many other molecules.The partnership commences immediately, and the companies have planned several joint activities .

我们认为，Nanoform的技术非常适合日本市场，在日本市场，提供生物利用度更高、剂量越来越少的药物对成功至关重要。”纳米技术在多种给药途径（包括口服，吸入，眼科和注射剂）以及多种分子类型（如恩扎鲁胺和许多其他分子）的几项体外和体内研究中均有效。合伙关系立即开始，两家公司计划开展多项联合活动。